Q-omics provides the consensus-scored RPL31P30 profile across patient tissues and cancer cell-line models. RPL31P30 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, RPL31P30 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, RPL31P30 RNA expression shows 14,580 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, THCA, and UVM as cancer lineages where RPL31P30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL31P30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL31P30 survival associations across molecular data types. RPL31P30 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL31P30 RNA expression–survival associations across cancer types. High RPL31P30 expression shows unfavorable associations in COAD and ACC, but favorable associations in OV, KIRP, BRCA and PAAD. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify COAD as the clearest survival context for RPL31P30 RNA expression.
This table summarizes RPL31P30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL31P30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL31P30 shows lower tumor expression in THCA, KICH and KIRC and higher tumor expression in LIHC, ESCA and LUSC. The THCA box plot shows higher RPL31P30 RNA expression in normal versus tumor tissue (log2 FC = −1.408, t-test p < 0.001).
This table shows molecular features associated with RPL31P30 in patient tissues and cancer cell lines. In patient samples, RPL31P30 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
